A Phase I Evaluation of the Effect of Ketoconazole on the Pharmacokinetics and Safety of Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004) in Healthy Volunteers Compared to DHE Delivered Intravenously (DHE 45).

Trial Profile

A Phase I Evaluation of the Effect of Ketoconazole on the Pharmacokinetics and Safety of Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004) in Healthy Volunteers Compared to DHE Delivered Intravenously (DHE 45).

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary) ; Ketoconazole
  • Indications Migraine; Mycoses
  • Focus Pharmacokinetics
  • Sponsors Allergan
  • Most Recent Events

    • 15 Dec 2011 Results published in the Cephalalgia.
    • 07 Nov 2011 Simbec Research added as a trial associate as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Trial location added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top